|

TNG462 Clinical Trials

3 actively recruiting trials across 3 locations

Pipeline

Phase 1/2: 3

Top Sponsors

  • Tango Therapeutics, Inc.2
  • Servier Bio-Innovation LLC1

Indications

  • Cancer3
  • Lung Cancer2
  • Liver Disease1
  • MTAP Deletion1
  • MTAP-deleted Solid Tumors1

Scottsdale, Arizona1 trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Mayo Clinic Scottsdale

Phase 1/2

Los Angeles, California1 trial

S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

University of California Los Angeles

Phase 1/2

Palo Alto, California1 trial

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Stanford University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.